01733nas a2200181   4500008004100000245007800041210006900119260000800188300002200196490000700218520109300225100002801318700002001346700002701366700002601393700002001419856011201439       2018                        eng d00aCurcumin-artemisinin coamorphous solid: Xenograft model preclinical study0 aCurcuminartemisinin coamorphous solid Xenograft model preclinica  cMAR  aArticle Number: 70 v103 aCurcumin is a natural compound present in Indian spice turmeric. It has diverse pharmacological action but low oral solubility and bioavailability continue to limit its use as a drug. With the aim of improving the bioavailability of Curcumin (CUR), we evaluated Curcumin-Pyrogallol (CUR-PYR) cocrystal and Curcumin-Artemisinin (CUR-ART) coamorphous solid. Both of these solid forms exhibited superior dissolution and pharmacokinetic behavior compared to pure CUR, which is practically insoluble in water. CUR-ART coamorphous solid showed two fold higher bioavailability than CUR-PYR cocrystal (at 200 mg/kg oral dose). Moreover, in simulated gastric and intestinal fluids (SGF and SIF), CUR-ART is stable up to 3 and 12 h, respectively. In addition, CUR-PYR and CUR-ART showed no adverse effects in toxicology studies (10 times higher dose at 2000 mg/kg). CUR-ART showed higher therapeutic effect and inhibited approximately 62% of tumor growth at 100 mg/kg oral dosage of CUR in xenograft models, which is equal to the positive control drug, doxorubicin (2 mg/kg) by i.v. administration.1 aMannava, M., K. Chaitan1 aSuresh, Kuthuru1 aBommaka, Manish, Kumar1 aKonga, Durga, Bhavani1 aNangia, Ashwini  uhttps://library.ncl.res.in/content/curcumin-artemisinin-coamorphous-solid-xenograft-model-preclinical-study